TGTX (TG Therapeutics) Valuation Rank


TGTX TG Therapeutics Inc TGTX
82 GF Score
Price $53.31
GF Value $58.68
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is TG Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

TG Therapeutics Valuation Rank Related Terms

TGTX
82GF Score
TG Therapeutics Inc TGTX
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is TG Therapeutics (TGTX) Overvalued in 2026?

Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued. The current stock price of $53.31 is trading 9.2% below its estimated GF Value™ of $58.68. GuruFocus considers TG Therapeutics to be Fairly Valued.

Key valuation signals for TGTX:

  • Valuation Rank:
  • GF Value™: $58.68 vs. price of $53.31 (9.2% below fair value)
  • GF Score™: 82/100 with 8 warning signs

No single metric tells the full story. See the TGTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TG Therapeutics Business Description

Other Exchanges 1TGTX:ItalyNKB2:Germany
Address 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
82GF Score

Get the complete analysis for TGTX

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$53.31
Price
$58.68
GF Value